Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsBio-TheraSolutions, a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosesimilars hassigned an exclusive License and Commercialisation Agreement with WorldMedicine , Türkiye'spharmaceutical export champion, continuingits mission of providing accessible an...
Guangzhou, China – Bio-Thera Solutions, Ltd. today announced thepublication of the Phase Iclinical study results for BAT4406F, an ADCC-enhanced fully humanized anti-CD20monoclonal antibody in Chinese patients with neuromyelitis optica spectrumdisorders (NMOSD) in the journal CNS Neuroscience Thera...
Guangzhou, China, December 24, 2024 - Bio-TheraSolutions Inc. (688177:SH),a commercial-stage biopharmaceutical company developing a pipeline ofinnovative therapies and a pipeline of biosesimilars, today announced the companyhas partnered with Tabuk PharmaceuticalManufacturing Company (a fully-ownedsub...
